KLRS

Kalaris Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 5/10
  • Momentum↑ 9/10
Kalaris Therapeutics sales and earnings growth
KLRS Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 84.33%
  • FCF Y/Y↑ 19.92%
Kalaris Therapeutics gross and profit margin trends
KLRS Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -842.00%
Kalaris Therapeutics net debt vs free cash flow
KLRS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -34.8

Kalaris Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗